A Variant of Acute Promyelocytic Leukemia with t(4;17)(q12;q21) Showed Two Different Clinical Symptoms | Zendy

Takahisa� Nakanishi | Zendy; Aya Nakaya | Zendy; Yusuke Nishio | Zendy; Shinya� Fujita | Zendy; Atsushi� Satake | Zendy; Yoshiko� Azuma | Zendy; Yukie� Tsubokura | Zendy; Ryo� Saito | Zendy; Akiko� Konishi | Zendy; Masaaki� Hotta | Zendy; Hideaki� Yoshimura | Zendy; Yoshihiko Kadosaka | Zendy; Kazuyoshi� Ishii | Zendy; Tomoki Ito | Zendy; Koji Tsuta | Zendy; Shosaku� Nomura | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Variant of Acute Promyelocytic Leukemia with t(4;17)(q12;q21) Showed Two Different Clinical Symptoms

Author(s) -

Takahisa� Nakanishi,

Aya Nakaya,

Yusuke Nishio,

Shinya� Fujita,

Atsushi� Satake,

Yoshiko� Azuma,

Yukie� Tsubokura,

Ryo� Saito,

Akiko� Konishi,

Masaaki� Hotta,

Hideaki� Yoshimura,

Yoshihiko Kadosaka,

Kazuyoshi� Ishii,

Tomoki Ito,

Koji Tsuta,

Shosaku� Nomura

Publication year - 2019

Publication title -

hematology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.239

H-Index - 12

ISSN - 2038-8330

DOI - 10.4081/hr.2019.7971

Subject(s) - acute promyelocytic leukemia , medicine , myeloid leukemia , retinoic acid , leukemia , myeloid , complete remission , chemotherapy , cancer research , oncology , biology , cell culture , genetics

A 63-year-old man was diagnosed with a rare variant of acute promyelocytic leukemia (APL) with t(4;17)(q12; q21) that showed atypical morphological features and two different clinical symptoms. He was started on standard induction chemotherapy for acute myeloid leukemia, which decreased myeloblast numbers; however, APL-like blasts remained. He then received a salvage therapy that added all retinoic acid (ATRA). After ATRA commenced, APL-like blasts disappeared and cytogenetic analysis became normal. However, myeloblasts subsequently increased, and he became resistant. In summary, this patient exhibited two different clinical courses of acute myeloid leukemia and APL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research